Auscann Group Holdings Ltd

AC8 Details

Appointment of Medical Liaison Managers: AusCann Group Holdings Ltd (ASX: AC8) has appointed three Medical Liaison Managers (MLMs), to manage doctor communications and assist in the prescription of its cannabinoid medicines in Australia. It has a deep knowledge of cannabinoid medicines, particularly in the application for chronic pain, through the extensive experience and knowledge of its Canadian Chief Medical Advisor as well as through its international partnership with Canopy Growth Corporation (largest medical cannabis producer in North America). Canopy is providing the initial cannabis medicines to AusCann as Australian production is progressed and the MLMs are responsible for leading engagement programs in their regions, expanding relationships and providing guidance and information to key medical practitioners. Each appointee has an impressive track record as representatives of medications governed by the Therapeutic Goods Administration (TGA), and most importantly are well versed about the treatment of chronic pain. Moreover, Chronic, and, chronic neuropathic pain is a key target indication for the company, with a significant number of studies indicating that cannabinoids have a positive impact on reducing pain as the need for chronic pain control is significant in Australia representing around 3.2 million people.

Further, in combination with DayaCann (licensed joint-venture in Chile) and an exclusive strategic partnership with Tasmanian Alkaloids Pty Ltd, AC8 is well positioned to be a leading player in the global medicinal cannabis market.We maintain a “Buy” recommendation on the stock at the current market price of $ 0.50

Creso Pharma Ltd

CPH Details

Significant progress for animal and human health nutraceuticals: For H1FY17, Creso Pharma Ltd (ASX: CPH) posted a net loss after tax of A$3.53 million including a non?cash cost of A$1.19 million for share?based payment expenses associated with options and performance rights issued during the period. CPH has successfully completed a placement to institutional and professional investors by raising A$8.8 million, while a Share Purchase Plan raised an additional A$1 million. The funds raised under the Placement and SPP are being used to fast?track the commercialisation of the Company’s cannabinoid?derived animal and human health nutraceuticals and other medical cannabis products and to expand the development pipeline. Further, the group has reported for significant progress with regards to the development and commercialisation plans for the first animal and human health nutraceutical products. It is also the first company to successfully import medicinal cannabis products in Australia.

The stock declined over 36% in the last six months while it is up 128% on year to date basis (as of September 20, 2017). Given the improving prospects and demand for cannabis, we maintain a “Hold” at the current price of $ 0.50

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.